1. In Vivo
  2. >>Market Intelligence

Immunotherapies Set To Spark Alzheimer's Drug Market

 
• By Nancy Dvorin

Five late-stage Alzheimer's disease candidates, three of them monoclonal antibodies, are projected to rack up big sales when they launch, according to a new report by Datamonitor Healthcare. Like the rest of the AD drug market, growth for these products will come from treating earlier stages of the disease (article free with registration).

Sales of Alzheimer’s disease drugs across the US, Japan and five major EU markets (France, Germany, Italy, Spain and the UK) totaled $3.1 billion in 2015. By 2024, the AD market is forecast to reach $12.6 billion, a compound annual growth rate (CAGR) of 16.83%, according to "Alzheimer's Disease Forecast," a new report by Informa's Datamonitor Healthcare analyst Maha Elsayed, PhD.

The US is the largest major market for Alzheimer’s disease drugs, with an estimated 2015 value of $1.75 billion. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.